KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Non-Current Debt (2021 - 2025)

Historic Non-Current Debt for Halozyme Therapeutics (HALO) over the last 6 years, with Q4 2025 value amounting to $2.1 billion.

  • Halozyme Therapeutics' Non-Current Debt rose 4229.2% to $2.1 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $2.1 billion, marking a year-over-year increase of 4229.2%. This contributed to the annual value of $2.1 billion for FY2025, which is 4229.2% up from last year.
  • Per Halozyme Therapeutics' latest filing, its Non-Current Debt stood at $2.1 billion for Q4 2025, which was up 4229.2% from $800.1 million recorded in Q3 2025.
  • In the past 5 years, Halozyme Therapeutics' Non-Current Debt ranged from a high of $2.1 billion in Q4 2025 and a low of $787.3 million during Q4 2021
  • In the last 5 years, Halozyme Therapeutics' Non-Current Debt had a median value of $1.5 billion in 2023 and averaged $1.4 billion.
  • In the last 5 years, Halozyme Therapeutics' Non-Current Debt surged by 8961.66% in 2022 and then tumbled by 4680.92% in 2025.
  • Halozyme Therapeutics' Non-Current Debt (Quarter) stood at $787.3 million in 2021, then skyrocketed by 89.62% to $1.5 billion in 2022, then grew by 0.43% to $1.5 billion in 2023, then rose by 0.44% to $1.5 billion in 2024, then surged by 42.29% to $2.1 billion in 2025.
  • Its last three reported values are $2.1 billion in Q4 2025, $800.1 million for Q3 2025, and $1.5 billion during Q2 2025.